TBPH

Theravance Biopharma Inc

TBPH, USA

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

https://www.theravance.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TBPH
stock
TBPH

How (TBPH) Movements Inform Risk Allocation Models news.stocktradersdaily.com

Read more →
TBPH
stock
TBPH

Forecast Cut: Can Nostrum Oil Gas PLC 3NO0 stock expand revenue streams - Trend Reversal & Trade Opportunity Analysis Reports moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$26.7143

Analyst Picks

Strong Buy

1

Buy

1

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Medium

33.14

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

4.05

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

1.55 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

0.87 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-32.56 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Low

0.79

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 92.66% of the total shares of Theravance Biopharma Inc

1.

Madison Avenue Partners, LP

(18.8858%)

since

2025/06/30

2.

Weiss Asset Management LP

(14.8071%)

since

2025/06/30

3.

Newtyn Management LLC

(9.829%)

since

2025/06/30

4.

BlackRock Inc

(8.2187%)

since

2025/06/30

5.

Irenic Capital Management LP

(5.4823%)

since

2025/06/30

6.

Vanguard Group Inc

(4.2839%)

since

2025/06/30

7.

Park West Asset Management LLC

(3.5723%)

since

2025/06/30

8.

Vanguard Total Stock Mkt Idx Inv

(2.2586%)

since

2025/07/31

9.

Oasis Management Co. Ltd

(2.2218%)

since

2025/06/30

10.

State Street Corp

(2.0564%)

since

2025/06/30

11.

D. E. Shaw & Co LP

(1.9892%)

since

2025/06/30

12.

iShares Russell 2000 ETF

(1.8329%)

since

2025/08/31

13.

Geode Capital Management, LLC

(1.7751%)

since

2025/06/30

14.

Dimensional Fund Advisors, Inc.

(1.4338%)

since

2025/06/30

15.

Morgan Stanley - Brokerage Accounts

(1.0933%)

since

2025/06/30

16.

Bank of America Corp

(1.0715%)

since

2025/06/30

17.

Royal Bank of Canada

(1%)

since

2025/06/30

18.

Citadel Advisors Llc

(0.9637%)

since

2025/06/30

19.

Camber Capital Management LLC

(0.8935%)

since

2025/06/30

20.

UBS Group AG

(0.7886%)

since

2025/06/30

21.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7719%)

since

2025/07/31

22.

BNP Paribas Arbitrage, SA

(0.7694%)

since

2025/06/30

23.

Fidelity Small Cap Index

(0.7531%)

since

2025/06/30

24.

Northern Trust Corp

(0.6994%)

since

2025/06/30

25.

iShares Biotechnology ETF

(0.5466%)

since

2025/08/31

26.

iShares Russell 2000 Growth ETF

(0.5371%)

since

2025/08/31

27.

BlackRock Global Equity Mkt Netrl Instl

(0.427%)

since

2025/07/31

28.

Macquarie Healthcare I

(0.4146%)

since

2025/07/31

29.

Fidelity Extended Market Index

(0.3845%)

since

2025/07/31

30.

Vanguard Russell 2000 ETF

(0.3582%)

since

2025/07/31

31.

Schwab US Small-Cap ETFâ„¢

(0.3357%)

since

2025/08/30

32.

BlackRock Advantage Small Cap Core Instl

(0.3121%)

since

2025/07/31

33.

DFA US Small Cap I

(0.2949%)

since

2025/07/31

34.

State St Russell Sm Cap® Indx SL Cl I

(0.277%)

since

2025/08/31

35.

Dimensional US Small Cap ETF

(0.25%)

since

2025/08/29

36.

Dimensional US Core Equity 2 ETF

(0.2385%)

since

2025/08/29

37.

Vanguard Health Care ETF

(0.2328%)

since

2025/07/31

38.

Janus Henderson Small Cap Gr Alpha ETF

(0.2173%)

since

2025/08/29

39.

DFA US Micro Cap I

(0.1956%)

since

2025/07/31

40.

Schwab Small Cap Index

(0.191%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.6104

Latest Release

Date

2025-09-30

EPS Actual

0.0435

EPS Estimate

-0.1335

EPS Difference

0.177

Surprise Percent

132.5843%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(1.5)
Momentum
Moderate Momentum(6)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(4)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.